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Penetration enhancerAbstract The aim of this work is to investigate penetration enhancers in proniosomes as a
transdermal delivery system for nisoldipine. This was performed with the goal of optimising the
composition of proniosomes as transdermal drug delivery systems. Plain proniosomes comprising
sorbitan monostearate, cholesterol, ethanol and a small quantity of water were initially prepared.
Subsequently, proniosomes containing lecithin or skin penetration enhancers were prepared and
evaluated for transdermal delivery of nisoldipine. The plain proniosomes signiﬁcantly enhanced
the transdermal ﬂux of nisoldipine to reach 12.18 lg cm2 h1 compared with a saturated aqueous
drug solution which delivered the drug at a rate of 0.46 lg cm2 h1. Incorporation of lecithin into
such proniosomes increased the drug ﬂux to reach a value of 28.51 lg cm2 h1. This increase can
be attributed to the penetration enhancing effect of lecithin fatty acid components. Replacing
lecithin oleic acid (OA) produced proniosomes of comparable efﬁcacy to the lecithin containing
system. The transdermal drug ﬂux increased further after incorporation of propylene glycol into
the OA based proniosomes. Similarly, incorporation of isopropyl myristate into plain proniosomes
increased drug ﬂux. The study introduced enhanced proniosomes as a promising transdermal
delivery carrier and highlighted the role of penetration enhancing mechanisms in enhanced
proniosomal skin delivery. The study opened the way for another line of optimisation of niosome
proconcentrates.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
The strategy of using lipid vesicles to improve drug delivery to
and across the skin has gained interest. These vesicles included
traditional liposomes (Mezei and Gulasekharam, 1980), trans-
fersomes (ultradeformable vesicles), and ethosomes (Cevc and
Blume, 1992; Touitou et al., 2000; El Maghraby et al., 2001).
However, most of liposomes were reported to have stability
problem and high cost. The stability problems of liposomes
are in the form of loss of entrapped drug, change in the size
upon storage as well as chemical degradation of the lipid com-
ponents (Sharma and Sharma, 1997). Accordingly, niosomes
68 G.M. El Maghraby et al.which are surfactant based vesicles that are more stable (chem-
ically) and less expensive than liposomes were introduced
(Schreier and Bouwstra, 1994; Manosroi et al., 2008). However,
although niosomes exhibit more chemical stability during stor-
age, there may be a physical stability problem upon storage of
niosome dispersion. Proniosomes were prepared as dry powder
for reconstitution before use as a means of preserving the
chemical and physical integrity of vesicles (Hu and Rhodes,
2000). For the transdermal delivery purpose proniosomes were
prepared as gel like concentrated niosomes suitable for topical
application (El Maghraby and Williams, 2009). These gel like
structures have the advantage of being suitable for scaling up
while maintaining the skin penetration enhancing abilities
and better physicochemical stability. However, the published
data on proniosomes are rare and are not systematic with many
factors requiring further investigation. These factors include
the effect of composition and the possibility of incorporating
traditional skin penetration enhancers into proniosomes.
Accordingly, the main aim of this study is to investigate the
effect of incorporation of skin penetration enhancers in pro-
niosomes on the transdermal delivering ability of this system.
To achieve this objective, nisoldipine a second-generation
dihydropyridine calcium antagonist was selected as the test
drug. This selection was based on the fact that the drug suffers
from low and variable bioavailability after oral administration.
This low bioavailability was attributed to the extensive ﬁrst
pass metabolism (Zannad, 1995; El Maghraby and
Elsergany, 2014). This together with its high potency made
the drug an excellent candidate for transdermal delivery. The
physicochemical properties of nisoldipine were also considered
in the selection of the drug candidate for this study. Nisoldi-
pine has a molecular weight of 388.4 Daltons and is highly
lipophilic as indicated from its high partition coefﬁcient (log
P= 3.63) (Marinkovic et al., 2003; El Maghraby and
Elsergany, 2014). The molecular weight (below 500 Daltons)
and lipophilicity provided nisoldipine with high potential for
transdermal delivery. The lipophilic nature of the drug is
another advantage for the current study due to expected high
entrapment efﬁciency in proniosomes and other vesicular sys-
tems (El Maghraby et al., 2001). The study will thus provide
dual functions as it will add a new factor in optimised transder-
mal delivery from provesicular systems and develop a method
for enhanced nisoldipine transdermal delivery.
2. Materials and methods
2.1. Materials
Sorbitan monostearate (Span 60), cholesterol and lecithin were
purchased from Sigma Chemical Co. (St. Louis, MO, USA).
Nisoldipine was purchased from Jinan Jianfeng Chemical
Co. Ltd., China. Methanol, acetonitrile (HPLC – grade) and
propylene glycol were obtained from BDH, England. Ethanol
(96%) and oleic acid were from El-Nasr Pharmaceutical
Chemicals Company, Egypt. Isopropyl myristate (IPM) was
a gift from Sigma for Pharmaceutical Industries, Egypt.
2.2. Preparation of proniosomes
Table 1 presents the composition of the tested proniosome for-
mulations. The surfactant mixture (Span 60 – cholesterol), thedrug, ethanol and penetration enhancer (if any) were mixed
and heated to 65 + 1 C for 5 min in a stoppered vessel. This
provided a clear liquid system. The aqueous phase was added
and the mixture was warmed upto clarity. The mixture was
allowed to cool down by continuous mixing at room tempera-
ture till the formation of a proniosome gel (Vora et al., 1998).
2.3. Determination of entrapment efﬁciency
To determine the entrapment efﬁciency of the drug into pro-
niosomes, the formulation was hydrated to develop the corre-
sponding niosome. This was achieved by hydrating the
proniosome gel (1 g) using 10 ml distilled water with the aid
of mechanical stirring for 30 min. The resulting niosomes were
subjected to 30 min of bath sonication. Immediately after
hydration of proniosomes, the niosome dispersion was incu-
bated in a dialysis sac (Cellulose tubing, cut off 12,000 Dal-
tons, Sigma diagnostics, St. Louis, MO, USA) and dialysed
against 100 ml of 40% v/v ethanol in water for 4 h. This dial-
ysis ﬂuid was selected to ensure sink conditions. The amount
of the drug found in the dialysate was taken as a measure of
the free drug. The entrapment efﬁciency was calculated by
the following equation (Trotta et al., 2002; Foco et al., 2005;
Maestrelli et al., 2005):
Entrapment efficiencyð%Þ ¼ ½ðCt  CfÞ=Ct  100:
where Ct is the total concentration of the drug and Cf is the
concentration of the free drug.
2.4. Viscosity measurements
The ﬂow behaviour and viscosity of the tested formulations
were determined using a DV III rotating Brookﬁeld viscometer
using spindle RV-3 (Brookﬁeld Engineering Laboratories Inc.,
Stoughton, MA, USA).
2.5. Determination of drug release
Drug release from vesicles is temperature dependent, generally
being greatest around the phase transition temperature of the
lipid (Papahadjopoulos et al., 1973). According to our experi-
mental conditions the skin surface was maintained at 32 C.
Accordingly, the drug release studies were conducted at
32 C to give a chance for correlation between drug release
and skin permeation data.
The release study employed the vertical glass Franz diffu-
sion cells which have a diffusional surface area of 2.27 cm2
with the receptor compartment of 14.5 ml volume. The dialysis
membrane (Cellulose tubing, Sigma diagnostics, St. Louis,
MO, USA) was soaked in distilled water overnight before cut-
ting into suitable pieces. This soaking was conducted to ensure
complete swelling of the membrane to provide a constant pore
diameter throughout the experiment. The membrane was then
mounted between the donor and receptor compartments
before ﬁlling the receptor compartment with 40% v/v ethanol
in water. This receptor ﬂuid was selected to maintain sink con-
ditions which was conﬁrmed by recording linear release pro-
ﬁles which did not tail off (see the results). The diffusion
cells were incubated into a thermostatically controlled water
bath with its temperature being adjusted to maintain the tem-
perature of the membrane surface at 32 + 1 C to mimic
Table 1 The composition of the tested formulations (expressed in grams per formulation) and the entrapment efﬁciency of the drug
into proniosomes.
Formulation Surfactant system* Ethanol Aqueous phase** IPM OA PG Entrapment eﬃciency (%)
P 5 5 4 – – – 84.1 ± 0.3
P/Lec. 5 5 4 – – – 80.3 ± 0.3
P/IPM 5 5 4 1 – – 87.7 ± 0.2
P/OA 5 5 4 – 1 – 88.2 ± 0.2
P/OA-PG0.5 5 5 4 – 1 0.5 83.5 ± 1.5
P/OA-PG1 5 5 4 – 1 1.0 84.5 ± 0.01
P/OA-PG1.5 5 5 4 – 1 1.5 84.8 ± 0.2
* The composition of the surfactant system in all formulations was Span 60 and cholesterol (4.5:0.5) except the formulation (P/lec) which
contained Span 60, cholesterol and lecithin (3.5:0.5:1) respectively.
** The aqueous phase was 0.1% glycerol in water. The amount of the drug added to each formulation was 0.3 g.
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donor compartments. Receptor samples were taken at differ-
ent time intervals and analysed for the drug by HPLC. These
samples were replaced with fresh receptor. The cumulative
amount of drug released was calculated as a function of time
(El Maghraby, 2010).
2.6. Preparation of skin samples
Ideally skin permeation experiments should employ human
skin. Unfortunately, it is difﬁcult to obtain good human skin
samples. Accordingly, the rabbit ear model which has been
extensively used for the investigation of transdermal delivery
of a variety of lipophilic drugs like our drug was employed
in this study (Corbo et al., 1990; Touitou et al., 2000; El
Maghraby, 2012). Full thickness skin obtained from the inner
side of freshly excised ears of 8 male rabbits (weighing 2–3 kg)
was used. The skin was peeled from the underlying cartilage
after cutting along the tips of ears. The skin samples were
mounted immediately on the diffusion cells (El Maghraby,
2008).
2.7. Skin permeation studies
As for the release studies, the vertical glass Franz diffusion
cells were employed in the skin permeation experiments. The
skin was mounted with the stratum corneal side uppermost
on the diffusion cells. To ensure sink conditions, 40% v/v eth-
anol in water was used as receptor. The diffusion cells were
incubated into a thermostatically controlled water bath with
its temperature being adjusted to maintain the temperature
of the skin surface at 32 + 1 C to mimic vivo conditions.
After overnight equilibration, the tested formulation of pro-
niosomes (2.5 g) was loaded into the donor compartments
which were occluded with aluminium foil. Receptor samples
were taken at different time intervals and analysed for the drug
by HPLC. These samples were replaced with fresh receptor.
The study ensured that skin obtained from the same rabbit
was used for the test and control (El Maghraby, 2010).
2.8. Chromatography
The drug concentrations in all samples were determined using
an HPLC analysis. This employed a high pressure liquid chro-
matograph (Waters 600 controller, USA) equipped with avariable wavelength detector (Waters 486, Tunable Absor-
bance Detector, USA) and an automatic sampling system
(Waters 717 Plus Autosampler, USA). This was under com-
puter control. Separation was accomplished on a reversed
phase column 15 cm · 4.6 mm (i.d.) C18, l Bondapak,
Waters, with an average particle size of 10 lm.
The mobile phase was a mixture of methanol, acetonitrile
and water (35:30:35) ﬂowing at 1.3 ml/min. The column efﬂu-
ent was monitored at 238 nm (El Maghraby and Elsergany,
2014). The chromatographic data analysis was performed with
the Millinium Programme (Waters, USA). The receptor sam-
ples (30 ll) were injected directly into the HPLC system.
2.9. Data analysis
The cumulative amounts of the drug permeated were plotted
as a function of time to produce the permeation proﬁles. The
plots were typical steady state proﬁles which are expected after
occlusive application of formulations containing excess
amounts of the drug (Fig. 1). These proﬁles were used to cal-
culate the transdermal drug ﬂux (J), which was obtained from
the slope of the regression line ﬁtted to the linear portion of the
proﬁle. Extrapolation of this line will intercept with the x axis
at a time equal to the lag time.
2.10. Statistical analysis
Students’ t-test was used to test for signiﬁcance.
3. Results
3.1. Entrapment efﬁciency
The recorded entrapment efﬁciency values are presented in
Table 1. The entrapment efﬁciency ranged from 80.3 + 0.3%
to 88.2 + 0.2%. With regard to the entrapment efﬁciency of
individual formulations, the plain proniosome formulation
(P) entrapped 84.1% of the added drug. This value was
increased further after incorporation of oleic acid or IPM into
the formulations. In contrast, incorporation of lecithin
resulted in a reduction of the entrapment efﬁciency of the drug
into proniosomes compared to that of the plain proniosomes.
Addition of propylene glycol with oleic acid reduced the
entrapment efﬁciency to become comparable to that of the
standard proniosomes (P).
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Figure 2 The viscosity of the tested proniosome formulations as
a function of the angular velocity. Formulation details are shown
in Table 1.
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Figure 1 The transdermal permeation proﬁles of nisoldipine
after the application of different proniosome formulations to
rabbit skin in vitro. The control was an saturated aqueous solution
of the drug. Formulation details are shown in Table 1.
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The ﬂow behaviour of the tested formulations followed a non-
Newtonian system with a shear thinning behaviour. This shear
thinning behaviour is shown in Fig. 2 which reveals a reduction
in the viscosity by increasing the shear rate. Having a non-New-
tonian ﬂow, the viscosity was calculated at a ﬁxed rpm
(50 rpm). The recorded viscosity values are presented in Table 2.
The plain proniosomes were the most viscous with incorpora-
tion of penetration enhancers into proniosomes reducing the
viscosity. Surprisingly, addition of propylene glycol to oleic
acid containing the formulation decreased the viscosity reduc-
ing effect of oleic acid but the viscosity of the resulting formu-
lation remained lower than the plain formulation.
3.3. Drug release
The release proﬁles of nisoldipine obtained from different pro-
niosomes are shown in Fig. 3. The recorded release proﬁles
were linear with lag time in all cases. The calculated release
rates are presented in Table 2. All proniosomes revealed signif-
icantly higher release rates compared with the saturated aque-
ous solution of the drug. With respect to the effect of
composition of proniosomes on the drug release, incorpora-
tion of various penetration enhancers resulted in a signiﬁcant
increase in the rate of nisoldipine release (P< 0.05) compared
with the plain formulation. Lecithin containing formulation
showed the highest release rate.3.4. Proniosomal skin delivery of nisoldipine
The transdermal permeation proﬁles of nisoldipine from dif-
ferent proniosomes formulations are shown in Fig. 1. These
proﬁles were typical steady-state proﬁles with a lag time which
is expected after occlusive application of formulations contain-
ing the drug at saturation with excess drug to maintain satura-
tion. The calculated permeation parameters are presented in
Table 2. All proniosomal formulations delivered the drug
through the skin at a signiﬁcantly higher rate compared to
the saturated aqueous control. This is clear from the recorded
transdermal ﬂux values which were signiﬁcantly higher in the
case of proniosomes. The increase in transdermal ﬂux was
associated with a trend of reduction in the lag time (Table 2).
The trend of lag time reduction after proniosomal application
in the current study indicates increased diffusivity and sup-
ports skin penetration enhancement of components. Incorpo-
ration of lecithin into the proniosomes resulted in a
signiﬁcant increase in transdermal drug ﬂux compared to the
plain formulation (P< 0.05).
With respect to the effect of penetration enhancers, incor-
poration of oleic acid into proniosomes resulted in signiﬁcant
increase in the transdermal ﬂux of nisoldipine compared with
the plain proniosomes (P< 0.05). The efﬁcacy of the oleic
acid containing system was comparable to that of the lecithin
based formulation (Table 2). The efﬁcacy of oleic acid based
proniosomes became even greater after incorporation of pro-
pylene glycol into proniosomes. This is clear after comparing
the transdermal drug ﬂux of oleic acid based proniosomes in
the presence and absence of increasing concentrations of pro-
pylene glycol (Table 2). The efﬁcacy of oleic acid/propylene
glycol combination was even better than that of lecithin after
incorporation into proniosomes.
Table 2 Characteristics, transdermal permeation parameters and release rate of nisoldipine obtained after the application of
nisoldipine in the form of proniosome formulations and saturated aqueous solution (control).
Drug formulation Viscosity (cp) Release rate (lg cm2 h1) Flux (lg cm2 h1) Lag time (h)
P 51,800 (1633) 15.3 (1.12) 12.18 (2.32) 0.99 (0.11)
P/lec 22,533 (467) 45.01 (3.28) 28.51 (2.83) 0.94 (0.36)
P/IPM 36,400 (1562) 29.1 (1.94) 23.97 (1.92) 0.59 (0.07)
P/OA 33,733 (929) 34.3 (3.82) 30.21 (3.46) 0.93 (0.37)
P/OA-PG0.5 39,650 (4854) 43.2 (1.16) 30.86 (2.94) 0.97 (0.43)
P/OA-PG1 44,067 (1023) 42.02 (1.98) 34.08 (1.35) 0.84 (0.17)
P/OA-PG1.5 51,733 (2034) 41.19 (2.97) 38.67 (5.07) 0.92 (0.21)
Control ND 9.7 (0.8) 0.46 (0.03) 1.7 (0.1)
Values between brackets are S.D. (n= 3). Formulation details are shown in Table 1.
Penetration enhancers in proniosomes as transdermal delivery systems 71As for oleic acid, incorporation of IPM into proniosomes
resulted in a signiﬁcant increase in the transdermal delivery
efﬁciency compared with the corresponding plain pronio-
somes. However, the efﬁcacy of the IPM based system was
lower than that of lecithin or oleic acid containing
proniosomes.
4. Discussion
The recorded entrapment efﬁciency values indicate that the
amounts of drug added to proniosomes was enough to saturate
the proniosome formulations. This will ensure equal thermo-
dynamic activity among the tested proniosomes. This is neces-
sary to ensure that any difference in transdermal drug delivery
efﬁciency will depend on the composition of proniosomes. The
high entrapment efﬁciency of nisoldipine in plain proniosomes
(P) is expected for such a lipophilic drug. Similar entrapment
efﬁciency patterns were recorded for lipophilic drugs like levo-
norgesterel, estradiol and tenoxicam (Vora et al., 1998; Fang
et al., 2001; Ammar et al., 2011). Incorporation of oleic acid
or IPM into proniosomes can add to the lipophilic domains
of proniosomes. Taking this into consideration with the high
solubility of nisoldipine in oleic acid and IPM (data not
shown), the increase in entrapment efﬁciency of the drug in
proniosomes can be explained. Incorporation of lecithin
resulted in a reduction of the entrapment efﬁciency of the drug
into proniosomes. This may suggest low solubility of the drug
in lecithin. Another possible explanation can be based on posi-
tioning of lecithin and oleic acid into the vesicular structure.
The former is known to intercalate in the lipid domains
between Span and cholesterol but the later associates forming
a pole within the vesicular structure (El Maghraby et al., 2004).
Based on this arrangement lecithin can compete with the drug
for a location within the vesicular membrane but the associa-
tion of oleic acid molecules could provide islets into which
more drug can be localised. It is important to note that the
addition of propylene glycol with oleic acid reduced the
entrapment efﬁciency to become comparable to that of the
standard proniosomes.
The shear thinning ﬂow behaviour of proniosomes (Fig. 2)
is an advantage as it will allow easy application and spreading
on the skin surface. The reduction in the viscosity of pronio-
somes after incorporation of penetration enhancers can be
explained on the base of the ﬂuidizing effect of the enhancers
on the lamellar structure of proniosomes (El Maghraby
et al., 2004).The in vitro release of nisoldipine from various pronioso-
mal formulations was studied at the same skin permeation
experimental conditions but the skin was replaced with artiﬁ-
cial semi-permeable membrane. This was conducted so as to
correlate the release results with the skin permeation data (El
Maghraby, 2010). The recorded linear release after a lag time
(Fig. 3) is similar to previously recorded patterns for pronio-
somes containing tenoxicam which is a lipophilic drug like
nisoldipine (Ammar et al., 2011). The recorded higher release
rates of nisoldipine from proniosomes compared to saturated
aqueous solution can be attributed to higher drug concentra-
tions in proniosomal formulations compared with aqueous
solution due to very poor solubility of such lipophilic drugs
in water. This will in turn result in a higher concentration gra-
dient in the case of proniosomes which is the main driving
force in passive diffusion through semi-permeable membranes.
With respect to the effect of composition of proniosomes on
drug release, the recorded increase in the release rate after
incorporation of various penetration enhancers can be attrib-
uted to the ﬂuidizing effect of the enhancers on the provesicu-
lar system. The release rate generally correlated with the
viscosity data with the most viscous formulation producing
the slowest release. This pattern was not the same in the pres-
ence of propylene glycol which resulted in a higher release rate
compared to the oleic acid containing formulation which was
less viscous (Table 2). It is important to highlight the inverse
relationship between the entrapment efﬁciency and the drug
release. Taking the entrapment efﬁciency as a measure of the
formulation ability to retain the drug, high entrapment efﬁ-
ciency should theoretically suggest slower release rate (El-
Laithy et al., 2011).
Ethical requirements and lack of good human skin samples
forced researchers to use other skin models (El Maghraby
et al., 2008). Accordingly, full thickness skin obtained from
the inner side of freshly excised rabbit ears was utilised in the
current study. This skin has been successfully used in various
transdermal permeation studies of lipophilic drugs like nisoldi-
pine (Touitou et al., 2000; El Maghraby et al., 2009). The
receptor ﬂuid was 40% (v/v) ethanol in water to ensure sink
conditions. Such a receptor has been successfully employed
as a receptor to monitor skin delivery of a lipophilic drug from
vesicular delivery systems (El Maghraby et al., 1999).
Successful transdermal delivery from proniosomes has been
reported in the literature with proniosomes comprising Spans
with cholesterol and ethanol. Those authors investigated the
potential skin delivery of ﬂurbiprofen from proniosomes and
0400
800
1200
1600
0 10 20 30
C
um
ul
at
iv
e 
am
ou
nt
 r
el
ea
se
d(
µg
 c
m
-2
)
Time (hr)
P/Lec
P
control
0
400
800
1200
0 10 20 30
C
um
ul
at
iv
e 
am
ou
nt
 r
el
ea
se
d(
µg
 c
m
- 2
)
Time (hr)
P/IPM
P
control
0
400
800
1200
0 10 20 30
C
um
ul
at
iv
e 
am
ou
nt
 r
el
ea
se
d(
µg
 c
m
- 2
)
Time (hr)
P/OA
P
control
0
400
800
1200
0 10 20 30
C
um
ul
at
iv
e 
am
ou
nt
 r
el
ea
se
d(
µg
 c
m
-2
)
Time (hr)
P/OA-PG0.5
P
control
0
400
800
1200
0 10 20 30
C
um
ul
at
iv
e 
am
ou
nt
 r
el
ea
se
d(
µg
 c
m
- 2
)
Time (hr)
P/OA-PG1
P
control
0
400
800
1200
0 10 20 30
C
um
ul
at
iv
e 
am
ou
nt
 r
el
ea
se
d(
µg
 c
m
- 2
)
Time (hr)
P/OA-PG1.5
P
control
Figure 3 The in vitro release proﬁles of nisoldipine from different proniosome formulations. The control was an saturated aqueous
solution of the drug. Formulation details are shown in Table 1.
72 G.M. El Maghraby et al.their corresponding vesicles. They investigated the effect of the
type of Span and revealed a dependence of the release rate and
diffusion rate of the drug on the type of such surfactant
(Mokhtar et al., 2008; Ibrahim et al., 2008). Other authorsincluded lecithin into proniosomes and recorded successful
transdermal delivery of a variety of drugs from these
proniosomes. These investigations revealed the success of these
systems in enhanced transdermal delivery of levonorgesterol,
Penetration enhancers in proniosomes as transdermal delivery systems 73estradiol and piroxicam (Vora et al., 1998; Fang et al., 2001;
Chandra and Sharma, 2008). However, none of these articles
provided direct comparison between lecithin free and lecithin
containing proniosomes using the same drug. Alternative
mechanisms have been suggested for the enhanced transdermal
drug delivery from proniosomes. The earliest one depended on
the possibility that proniosomes can form niosomes after mix-
ing with skin secretion in vivo or mixing with the back diffus-
ing receptor ﬂuid in vitro (Vora et al., 1998). Accepting this
hypothesis, the mechanism of action of proniosomes can be
similar to niosomes which can enhance the drug by adsorption
on or adhesion to the skin surface creating high thermody-
namic activity with subsequent drug transfer. Another possible
reason for niosome enhanced transdermal delivery can depend
on the penetration enhancing effect of the vesicle components
(Schreier and Bouwstra, 1994; Uchegbu and Vyas, 1998). Later
on, the hypothesis of transformation of proniosomes to nio-
somes after topical application was rejected (Fang et al.,
2001). This rejection was based on recording the drug in the
receptor in the ﬁrst 30 min after application. Authors consid-
ered this as a short time for niosome formation and subsequent
drug transfer. In addition the hydrated proniosomes (nio-
somes) were less efﬁcient compared to the corresponding pro-
niosomes. Authors suggested direct drug transfer from
proniosomes with a role for the penetration enhancing effect
of the non-ionic surfactant component of such systems (Fang
et al., 2001). However, studies comparing niosomes with pro-
niosomes, tested dilute niosomes, a process which may not
mimic the actual situation where proniosomes form niosomes
after topical application. Accordingly, the potential of pronio-
somes transformation into niosomes after application to the
skin cannot be rejected completely before constructing an
experiment comparing different dilutions of proniosomes with
respect to transdermal drug delivery.
The recorded superiority of lecithin containing pronio-
somes can be explained on the basis of the ability of lecithin
to mix with skin lipids creating a more permeable environment
and adding to the penetration enhancing effect of proniosome
components. Mixing of lecithin with skin is believed to be bet-
ter in the presence of ethanol which is a component of pronio-
somes (Junginger et al., 1991). Additionally, soya lecithin has
been reported to contain unsaturated fatty acids like oleic acid
and linoleic acid which have penetration enhancing properties
(Rita and Lakshmi, 2012). Accordingly, the superiority of lec-
ithin containing proniosomes can be explained on the basis of
the ﬂuidizing effect of these fatty acids on the vesicular mem-
brane (El Maghraby et al., 2004). This explanation is suggested
here taking into consideration that proniosomes have to form
niosomes after mixing with skin secretions or back diffusing
receptor ﬂuid before delivering the drug into and through
the skin. Another possible explanation for the superiority of
lecithin containing proniosomes can depend on the direct skin
penetration enhancing effect of the unsaturated fatty acid com-
ponents of lecithin. Both explanations considered the impor-
tance of the fatty acid components of lecithin in enhanced
transdermal delivery from proniosomes. To verify this impor-
tance other proniosomes formulations were devised with leci-
thin being replaced by pure skin penetration enhancers. Oleic
acid was used for this purpose both in the presence and
absence of propylene glycol which is known to provide a syn-
ergistic penetration enhancing effect with oleic acid (Barry,
1987; Larrucea et al., 2001;). In addition, proniosomescontaining IPM, a well known fatty acid ester which can
intervene with the lipid lamellae making them more permeable
(Gorukanti et al., 1999; El Maghraby et al., 2009), were
prepared and tested for the same purpose.
With respect to the effect of penetration enhancers, the efﬁ-
cacy of the oleic acid containing system was comparable to
that of the lecithin based formulation (Table 2). This suggests
that the enhancing effect of lecithin can be due to its fatty acid
components. The efﬁcacy of oleic acid based proniosomes was
enhanced further after incorporation of propylene glycol into
proniosomes. This ﬁnding implies a synergistic effect for pro-
pylene glycol with oleic acid even after incorporation into pro-
niosomes. Oleic acid is believed to intercalate between the lipid
bilayer of the intercellular lipid lamellae of the stratum cor-
neum leading to a more loose structure. This effect is believed
to be improved in the presence of propylene glycol which
allows for easy penetration of oleic acid into the skin (Barry,
1987; Larrucea et al., 2001;). This highlights the direct penetra-
tion enhancing effect of the proniosome components as an
important factor in the superiority of enhancer containing pro-
niosomes compared with plain ones. However, further mecha-
nistic investigations are required to conﬁrm this hypothesis.
Incorporation of IPM into proniosomes resulted in a similar
trend with the resulting provesicles being superior to the corre-
sponding plain proniosomes. However, the efﬁcacy of IPM
based system was lower than that of lecithin or oleic acid con-
taining proniosomes. This implies the need for further optimi-
sation of the IPM based system with respect to the enhancer
concentration. Finally, it is important to consider the penetra-
tion enhancing effect of ethanol which was employed as an
integral component of proniosomes. Ethanol is believed to
increase the diffusivity of drugs through the stratum corneum
(Barry, 1987). Great success was recorded for ethanol when
incorporated in a similar vesicular system (ethothomes) and
it was considered to act as skin enhancer by itself with a pos-
sible ﬂuidizing effect on the vesicular component. The latter
effect is considered important for vesicular transdermal drug
delivery (Touitou et al., 2000). The success of ethanol was also
recorded for enhanced transdermal drug delivery from micro-
emulsions (El Maghraby, 2008).5. Conclusion
Proniosomes are promising transdermal drug delivery systems
with their efﬁcacy being dependent on their composition.
Proper selection of the proniosome components may lead to
better utilisation of such formulations. Penetration enhancer
containing proniosomes were better than the corresponding
plain formulation. The mechanism(s) of enhanced transdermal
delivery from proniosomes requires further investigations
although the recorded data and the effect of composition sug-
gested the possibility for combined mechanisms. The article
thus provided a new composition for transdermal proniosomes
and opened gates for future research on optimisation of the
composition together with mechanistic investigations.References
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